Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim gets first EU approval for Actilyse for thrombotic occlusion-caused catheter dy

Boehringer Ingelheim gets first EU approval for Actilyse for thrombotic occlusion-caused catheter dy

2nd June 2008

Boehringer Ingelheim has announced that it has received its first approval within the EU for Actilyse (alteplase) 2mg as a treatment for patients with catheter dysfunction caused by thrombotic occlusion.

The compound has been approved for this new indication in Germany after a successful completion of the European mutual recognition procedure, with subsequent EU approvals of this new indication to follow throughout 2008 onwards.

Actilyse is currently registered in over 85 countries worldwide as a treatment for acute ischaemic stroke, acute massive pulmonary embolism and acute myocardial infarction.

The company reports that a dose of up to 2mg of the compound can be administered up to twice in the occluded central venous access device and can restore the function of catheters which have become dysfunctional as a result of thrombotic occlusion by activating plasminogen to dissolve clotting substance fibrin.

Dr Andreas Barner, member of the Board of Boehringer Ingelheim responsible for research, development and medicine worldwide, said: “Until now, there have been limited treatment options available in Europe to healthcare professionals to restore catheter function following thrombotic occlusion.

“In many cases, the only option has been to remove and replace the catheter.”

He added that the approval of this new indication is welcome news for physicians and patients.

In May 2007, Boehringer Ingelheim announced that Actlyse had been recommended for use as a treatment for acute ischaemic stroke in the UK by the National Institute for Health and Clinical Excellence.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.